Literature DB >> 12458250

Current medical treatment for tuberculosis.

Edward D Chan1, Michael D Iseman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12458250      PMCID： PMC1124748          DOI： 10.1136/bmj.325.7375.1282

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  33 in total

1.  Clinical update: impact of HIV protease inhibitors on the treatment of HIV-infected tuberculosis patients with rifampin.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1996-10-25       Impact factor: 17.586

2.  Low antituberculosis drug concentrations in patients with AIDS.

Authors:  C A Peloquin; A T Nitta; W J Burman; K F Brudney; J R Miranda-Massari; M E McGuinness; S E Berning; G T Gerena
Journal:  Ann Pharmacother       Date:  1996-09       Impact factor: 3.154

3.  Cost-effectiveness of directly observed versus self-administered therapy for tuberculosis.

Authors:  R D Moore; C P Chaulk; R Griffiths; S Cavalcante; R E Chaisson
Journal:  Am J Respir Crit Care Med       Date:  1996-10       Impact factor: 21.405

4.  National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome.

Authors:  D R Burwen; A B Bloch; L D Griffin; C A Ciesielski; H A Stern; I M Onorato
Journal:  Arch Intern Med       Date:  1995-06-26

5.  Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis.

Authors:  D L Horn; D Hewlett; C Alfalla; S Peterson; S M Opal
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

6.  Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic.

Authors:  M C Raviglione; D E Snider; A Kochi
Journal:  JAMA       Date:  1995-01-18       Impact factor: 56.272

7.  Treatment of tuberculosis and tuberculosis infection in adults and children. American Thoracic Society and The Centers for Disease Control and Prevention.

Authors:  J B Bass; L S Farer; P C Hopewell; R O'Brien; R F Jacobs; F Ruben; D E Snider; G Thornton
Journal:  Am J Respir Crit Care Med       Date:  1994-05       Impact factor: 21.405

Review 8.  Compliance and supervision of chemotherapy of tuberculosis.

Authors:  J A Sbarbaro; J B Sbarbaro
Journal:  Semin Respir Infect       Date:  1994-06

9.  Epidemiology of tuberculosis in the United States, 1985 through 1992.

Authors:  M F Cantwell; D E Snider; G M Cauthen; I M Onorato
Journal:  JAMA       Date:  1994-08-17       Impact factor: 56.272

10.  Preventive therapy for contacts of multidrug-resistant tuberculosis. A Delphi survey.

Authors:  M R Passannante; C T Gallagher; L B Reichman
Journal:  Chest       Date:  1994-08       Impact factor: 9.410
View more
  33 in total

1.  Current medical treatment for tuberculosis. Resources used for screening could be spent more usefully elsewhere.

Authors:  Ruth J Whitfield; Rosemary Khan; Anne Smith; Charlotte F J Rayner
Journal:  BMJ       Date:  2003-03-08

2.  The efficacy of the crude root bark extracts of Erythrina abyssinica on rifampicin resistant Mycobacterium tuberculosis.

Authors:  L Bunalema; C Kirimuhuzya; J R S Tabuti; P Waako; J J Magadula; N Otieno; J A Orodho; P Okemo
Journal:  Afr Health Sci       Date:  2011-12       Impact factor: 0.927

3.  Structure-activity relationships at the 5-position of thiolactomycin: an intact (5R)-isoprene unit is required for activity against the condensing enzymes from Mycobacterium tuberculosis and Escherichia coli.

Authors:  Pilho Kim; Yong-Mei Zhang; Gautham Shenoy; Quynh-Anh Nguyen; Helena I Boshoff; Ujjini H Manjunatha; Michael B Goodwin; John Lonsdale; Allen C Price; Darcie J Miller; Ken Duncan; Stephen W White; Charles O Rock; Clifton E Barry; Cynthia S Dowd
Journal:  J Med Chem       Date:  2006-01-12       Impact factor: 7.446

4.  Solid-phase total synthesis of kahalalide A and related analogues.

Authors:  Line Bourel-Bonnet; Karumanchi V Rao; Mark T Hamann; A Ganesan
Journal:  J Med Chem       Date:  2005-03-10       Impact factor: 7.446

5.  Pneumonia: ... and to tuberculosis as differential diagnosis in community acquired pneumonia.

Authors:  Takeharu Koga; Hisamichi Aizawa
Journal:  BMJ       Date:  2006-05-20

Review 6.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 7.  Multidrug-resistant to extensively drug resistant tuberculosis: what is next?

Authors:  Amita Jain; Pratima Dixit
Journal:  J Biosci       Date:  2008-11       Impact factor: 1.826

8.  Metabolic activity interferometer: description and calibration of an interferometric method to measure growth of mycobacteria.

Authors:  R R P Machado; E S Lima Filho; D F Jardim; M A A Ferreira; C G de Faria; R S Duarte; B Lesche
Journal:  Eur Biophys J       Date:  2008-07-26       Impact factor: 1.733

9.  Anti-tubercular activity of novel 4-anilinoquinolines and 4-anilinoquinazolines.

Authors:  Christopher R M Asquith; Neil Fleck; Chad D Torrice; Daniel J Crona; Christoph Grundner; William J Zuercher
Journal:  Bioorg Med Chem Lett       Date:  2019-07-10       Impact factor: 2.823

10.  Exertional dyspnea-related acidotic and sympathetic responses in patients with sequelae of pulmonary tuberculosis.

Authors:  Keisuke Miki; Ryoji Maekura; Toru Hiraga; Hisako Hashimoto; Seigo Kitada; Mari Miki; Kenji Yoshimura; Yoshitaka Tateishi; Teppei Sugano; Masaharu Motone
Journal:  J Physiol Sci       Date:  2010-01-20       Impact factor: 2.781
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.